Replies to post #84322 on Biotech Values

[DewDiligence]

TLCS prices IPO/SPO at $19/sh. Of the 50M shares being sold, 58% are in the IPO and 42% are in the SPO:

http://finance.yahoo.com/news/Talecris-Biotherapeutics-bw-1512899435.html?x=0&.v=1

Caveat emptor certainly applies when insiders are unloading $400M worth of their own stock under the cover of an IPO!

[genisi]

Baxter, CSL Behring, and Talecris also compete in the A1PI market with products aimed at boosting a protein that protects the lungs from inflammation. [A1PI is another name for alpha-1 antitrypsin.] Talecris said its A1PI Prolastin product had a 67 percent share of sales in the U.S. in 2008 and 90 percent in the European Union.

Kamada has submitted a BLA for its I.V. alpha-1 antitrypsin, and intends to advance its inhaled version into phase III in Europe.

[DewDiligence]

TLCR holds its first CC as a public company today (Tue) at 8:30am ET:

http://biz.yahoo.com/cc/0/109010.html

http://finance.yahoo.com/news/Talecris-Biotherapeutics-bw-1459915200.html?x=0&.v=1